<SEC-DOCUMENT>0001437749-17-015841.txt : 20170912
<SEC-HEADER>0001437749-17-015841.hdr.sgml : 20170912
<ACCEPTANCE-DATETIME>20170912071708
ACCESSION NUMBER:		0001437749-17-015841
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170912
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170912
DATE AS OF CHANGE:		20170912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KEMPHARM, INC
		CENTRAL INDEX KEY:			0001434647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				205894398
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36913
		FILM NUMBER:		171080044

	BUSINESS ADDRESS:	
		STREET 1:		2500 CROSSPARK ROAD, SUITE E126
		CITY:			CORALVILLE
		STATE:			IA
		ZIP:			52241
		BUSINESS PHONE:		319-665-2575

	MAIL ADDRESS:	
		STREET 1:		2500 CROSSPARK ROAD, SUITE E126
		CITY:			CORALVILLE
		STATE:			IA
		ZIP:			52241

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KEMPHARM INC
		DATE OF NAME CHANGE:	20080507
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kmph20170905_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
<head>
	<title>kmph20161107_8k.htm</title>

</head>
<body style="font-family: Times New Roman, Times, serif; margin-right: 10px; margin-left: 10px; cursor: auto;"><!-- Created by RDG HTML Converter -->
<hr style="margin: 3pt 0px; border: currentColor; border-image: none; width: 100%; height: 3px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<hr style="margin: 0px 0px 3pt; border: currentColor; border-image: none; width: 100%; height: 1px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="margin: 0pt; text-align: center; color: rgb(0, 0, 0); text-indent: 0pt; font-family: Times New Roman; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: center; color: rgb(0, 0, 0); text-indent: 0pt; font-family: Times New Roman; font-size: 18pt; background-color: rgb(255, 255, 255);"><b>UNITED STATES</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 18pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>WASHINGTON, D.C. 20549 </b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<hr style="margin: 3pt auto; border: currentColor; border-image: none; width: 25%; height: 1px; text-align: center; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 18pt;"><b>FORM 8-K </b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<hr style="margin: 3pt auto; border: currentColor; border-image: none; width: 25%; height: 1px; text-align: center; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>CURRENT REPORT </b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Date of Report (Date of Earliest Eve</b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>nt Reported):&nbsp;September 12</b><b>, 2017</b></font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<hr style="margin: 3pt auto; border: currentColor; border-image: none; width: 25%; height: 1px; text-align: center; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 24pt;"><b>KemPharm, Inc.</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Exact Name of Registrant as Specified in Its Charter) </b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<hr style="margin: 3pt auto; border: currentColor; border-image: none; width: 25%; height: 1px; text-align: center; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL1" style="width: 100%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Delaware</b></p>
			</td>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>001-36913</b></p>
			</td>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>20-5894398</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(State or Other Jurisdiction</b></p>

			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>of Incorporation)</b></p>
			</td>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Commission File Number)</b></p>
			</td>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(IRS Employer</b></p>

			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Identification No.)</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 33.3%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 33.3%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>2500 Crosspark Road, Suite E126</b></p>

			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Coralville, IA</b></p>
			</td>
			<td style="width: 33.3%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>52241</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Address of Principal Executive Offices)</b></p>
			</td>
			<td style="width: 33.3%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Zip Code)</b></p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Registrant<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&rsquo;s Telephone Number, Including Area Code: </font></b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(319) 665-2575</b></font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Not Applicable </b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Former Name or Former Address, if Changed Since Last Report) </b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<hr style="margin: 3pt auto; border: currentColor; border-image: none; width: 25%; height: 1px; text-align: center; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB2" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 24pt; vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&#9744;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB3" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 24pt; vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&#9744;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB4" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 24pt; vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&#9744;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB5" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 24pt; vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&#9744;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect; 240.12b-2 of this chapter).</font></p>

<p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Emerging growth company&nbsp;&nbsp; &#9746;</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">) of the Exchange Act.&nbsp;&nbsp; &#9746;</font></p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Regulation FD Disclosure</b><b>.</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">On<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;September 12, 2017, KemPharm, Inc., or the Company, issued a press release announcing the completion of the Formal Dispute Resolution Request, or FDRR, process with the U.S. Food and Drug Administration, or FDA, for Apadaz&trade; (benzhydrocodone and acetaminophen). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. </font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Also on<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;September 12, 2017, the Company will conduct a conference call and live audio webcast to discuss these matters.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">shall not be deemed &quot;filed&quot; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is not incorporated by reference into any of the Company&#39;s filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.</font></p>

<p style="margin: 0pt 7.5pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Item 8.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other Events.</b></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">In the press release described above, on September<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> 12, 2017, the Company announced the completion of the FDRR process with the FDA for Apadaz&trade;. Following detailed discussions with the FDA,&nbsp;the Company&nbsp;has responded to the Complete Response Letter received on June 13, 2016, by submitting an amended New Drug Application, or NDA, for Apadaz&trade;. The FDA has notified the Company with the determination that the NDA application for Apadaz&trade; is complete and has assigned February 23, 2018 as the expected date by which an approval decision will be determined.&nbsp;Apadaz&trade; is the Company&rsquo;s investigational product candidate that is intended to provide short-term management of acute pain.</font></p>

<p style="margin: 0pt 7.5pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Caution Concerning Forward Looking Statements</b></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">This<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;Current Report on Form 8-K and the materials furnished herewith&nbsp;may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Exchange Act.&nbsp;Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;potential,&rdquo; &ldquo;should,&rdquo; &ldquo;continue&rdquo; or the negative versions of those words or other comparable words. These forward-looking statements include statements regarding the potential outcome of the FDA&rsquo;s review of the amended NDA for Apadaz&trade;, the potential labeling for Apadaz&trade;, the potential commercial pathway for Apadaz&trade; and the expected features and characteristics of KemPharm&rsquo;s product candidates, including Apadaz&trade;. These forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to&nbsp;the Company&nbsp;and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#39;s financial resources and whether they will be sufficient to meet the Company&#39;s business objectives and operational requirements; results of earlier studies and trials may not be predictive of future clinical trial results; the protection and market exclusivity provided by the Company&#39;s intellectual property; risks related to the drug discovery and the regulatory approval process; the impact of competitive products and technological changes; and the FDA approval process under the Section 505(b)(2) regulatory pathway, including without limitation any timelines for related approval. The Company&#39;s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company&rsquo;s business are described in additional detail in the Company&#39;s Quarterly Report on Form 10-Q for the period ended June 30, 2017, and the Company&rsquo;s other Periodic and Current Reports filed with the Securities and Exchange Commission.&nbsp;The Company&nbsp;is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.</font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Financial Statements and Exhibits.</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB6" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 27pt; vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">(d)</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibits</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL7" style="width: 100%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 10.6%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Exhibit<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;No.</font></b></p>
			</td>
			<td style="width: 1.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 87.5%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Description</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 10.6%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">99.1</p>
			</td>
			<td style="width: 1.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 87.5%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Press Release titled &ldquo;KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz&trade; NDA<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&rdquo;&nbsp;dated&nbsp;September 12, 2017.</font></p>
			</td>
		</tr>

</table>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>SIGNATURES</b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL8" style="width: 100%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 45.4%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 49.6%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Kem</b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Pharm</b></font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>, Inc</b></font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>.</b></font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: middle;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.2%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 46.4%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Date:&nbsp;September 12<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">, 2017</font></p>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.2%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">By:</p>
			</td>
			<td style="width: 46.4%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">/s/ Timothy J. Sangiovanni</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.2%; vertical-align: middle;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>
			</td>
			<td style="width: 46.4%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Timothy J. Sangiovanni, CPA</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.2%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>
			</td>
			<td style="width: 46.4%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Vice President, Corporate Controller</p>
			</td>
		</tr>

</table>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>EXHIBIT <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">INDEX</font></b></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL9" style="width: 100%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 10.6%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Exhibit<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;No.</font></b></p>
			</td>
			<td style="width: 1.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 87.5%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Description</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 10.6%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">99.1</p>
			</td>
			<td style="width: 1.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 87.5%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Press R<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">elease titled &ldquo;</font>KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz&trade; NDA<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&rdquo;&nbsp;dated&nbsp;September 12, 2017.</font></p>
			</td>
		</tr>

</table>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
	<title>ex99-1.htm</title>

</head>
<body style="font-family: Times New Roman, Times, serif; margin-right: 10px; margin-left: 10px; cursor: auto;"><!-- Created by RDG HTML Converter -->
<table border="0" cellpadding="0" cellspacing="0" id="TBL22" style="width: 32.2%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 100%; vertical-align: top;">
			<p style="margin: 0pt 0pt 0pt 81pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><img src="ex99-1img001.jpg" style="width: 57pt; height: 40pt; float: left;"></p>
			</td>
		</tr>
		<tr>
			<td style="width: 100%; vertical-align: top;">
			<p style="margin: 0pt 0pt 0pt 36pt; text-align: center; text-indent: 18pt; font-family: Times New Roman, Times, serif; font-size: 10pt;"><img src="ex99-1img002.jpg" style="width: 150pt; height: 29pt; float: left;"></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>EXHIBIT 99.1</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 12pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 12pt;"><b>KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz&trade; NDA</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 12pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><i>FDA Has Assigned a PDUFA Action Date of February 23, 2018</i></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><i>Conference Call and Live Audio Webcast Today at 8:30 a.m. ET</i></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Coralville, IA <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&ndash; September 12, 2017 &ndash;</font></b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> KemPharm, Inc. (NASDAQ: KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced completion of the Formal Dispute Resolution Request (FDRR) process with the U.S. Food and Drug Administration (FDA) for Apadaz&trade; (benzhydrocodone and acetaminophen). Following detailed discussions with the FDA, KemPharm has responded to the Complete Response Letter (CRL) received on June 13, 2016 by submitting an amended New Drug Application (NDA) for Apadaz&trade;. The FDA has notified the Company with the determination that the NDA application for Apadaz&trade; is complete and has assigned February 23, 2018 as the expected date by which an approval decision will be determined. Apadaz&trade; is KemPharm&rsquo;s investigational product candidate that is intended to provide short-term management of acute pain</font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&ldquo;<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">We are very pleased to have completed the FDRR process and are appreciative of the FDA&rsquo;s response,&rdquo; stated Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm.&nbsp;&ldquo;The discussions with the FDA provided clarity in the areas of disagreement concerning the appropriate information for the Apadaz&trade; product label, especially their determination that intranasal abuse of immediate release hydrocodone/acetaminophen is a relevant concern. If approved, we believe that there may be a potential commercial pathway for which truthful and non-misleading information about our clinical data can be included in the labeling, subject to review of our amended NDA for Apadaz&trade; by the FDA.&rdquo;</font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&ldquo;<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">When we initiated the FDRR process, it was done with the expectation that it would provide an open forum to discuss questions of science and policy involving appropriate labeling language for Apadaz&trade;,&rdquo; added Dan Cohen, Executive Vice President, Government and Public Relations. &ldquo;While the FDA formally denied our appeal in the FDRR due to the nature of the label dispute in the CRL, they provided us with valuable insights into the criteria that the FDA will use to evaluate the label information we submitted in our amended NDA for Apadaz&trade;. We thank the Review Division, Office of Drug Evaluation II, Office of New Drugs, and the Center for Drug Evaluation and Research (CDER) for their time and professionalism throughout the FDRR review.&rdquo; </font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">KemPharm initiated the FDRR process with the FDA on November 3, 2016, to appeal the CRL for Apadaz&trade;.<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;The appeal was submitted in accordance with the FDRR process following an end-of-review meeting in August 2016 in which the FDA provided the Company with a more complete understanding of its assessment of the NDA. The FDRR process is designed to provide a mechanism for those seeking regulatory approval of a drug product pursuant to an NDA to obtain formal review of any FDA decision.&nbsp;KemPharm believes its amended NDA for Apadaz&trade; addresses the points raised in the CRL and the amended NDA was resubmitted in accordance with applicable federal regulations for the approval of a new medicinal product (21 CFR 314.110)</font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">.</font></p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><u><b>Conference Call Information:</b></u></p>

<p style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">The company will host a conference call and live audio webcast today, September 12, 2017, at 8:30 a.m. ET. <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Interested participants and investors may access the conference call by dialing either:</font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB19" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 26pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-right: 7.5pt; margin-bottom: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-right: 7.5pt; margin-bottom: 0pt;">(866) 395-2480 (U.S.)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB20" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 26pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-right: 7.5pt; margin-bottom: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-right: 7.5pt; margin-bottom: 0pt;">(678) 509-7538 (international)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB21" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 26pt; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-right: 7.5pt; margin-bottom: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-right: 7.5pt; margin-bottom: 0pt;">Conference ID: 84323733</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">The live webcast will be accessible via the Investor Relations section of the KemPharm website <u><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">http://investors.kempharm.com/</font></u><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">.&nbsp;An archive of the webcast will remain available following the call</font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">.</font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>About the FDA<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&rsquo;s Formal Dispute Resolution Proces</font></b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>s</b></font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">KemPharm<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&rsquo;s appeal was submitted in accordance with the FDRR process that exists within FDA&#39;s CDER. FDA regulations provide a mechanism for those seeking regulatory approval of a drug product pursuant to an NDA to obtain formal review of any FDA decision. The process exists to encourage open, prompt discussion of scientific (including medical) disputes and procedural (including administrative) disputes that arise during the drug development, NDA review, and post-marketing oversight processes.&nbsp;While the FDA rarely grants an appeal during the FDRR process, companies are often able to gain further clarity into the FDA&rsquo;s regulatory requirements for product approval.&nbsp;With this clarity, companies may further assess if the FDA requirements for obtaining regulatory approval will still allow a product candidate to be commercially viable</font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>About the FDA<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&rsquo;s Prescription Drug User Fee Ac</font></b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>t</b></font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">PDUFA was a law passed by the US Congress initially in 1992, and reauthorized recently in 2017, which allows the FDA to collect fees from drug manufacturers to fund the new drug approval process. <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">PDUFA dates are deadlines for the FDA to approve new drugs. The FDA is normally given 10 months to review new drugs. If a drug is selected for priority review, the FDA is allotted 6 months to review the drug. These time frames begin on the date that an NDA is accepted by the FDA as complete</font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">.</font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>About KemPhar</b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>m</b></font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its LAT&trade;<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> (Ligand Activated Therapy) platform technology.&nbsp;KemPharm utilizes its LAT&trade; platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. KemPharm&rsquo;s lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release profiles for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company&rsquo;s immediate release abuse deterrent hydrocodone product candidate, KP201.&nbsp;For more information on KemPharm and its pipeline of prodrug product candidates visit </font><u><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">www.kempharm.com</font></u><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">.</font></p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Caution Concerning Forward Looking Statements</b></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;potential,&rdquo; &ldquo;should,&rdquo; &ldquo;continue&rdquo; or the negative versions of those words or other comparable words. These forward-looking statements include statements regarding the potential outcome of the FDA&rsquo;s review of the amended NDA for Apadaz&trade;, the potential labeling for Apadaz&trade;, the potential commercial pathway for Apadaz&trade; and the expected features and characteristics of KemPharm&rsquo;s product candidates, including Apadaz&trade;. These forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: KemPharm&#39;s financial resources and whether they will be sufficient to meet KemPharm&#39;s business objectives and operational requirements; results of earlier studies and trials may not be predictive of future clinical trial results; the protection and market exclusivity provided by KemPharm&#39;s intellectual property; risks related to the drug discovery and the regulatory approval process; the impact of competitive products and technological changes; and the FDA approval process under the Section 505(b)(2) regulatory pathway, including without limitation any timelines for related approval. KemPharm&#39;s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning KemPharm&rsquo;s business are described in additional detail in KemPharm&#39;s Quarterly Report on Form 10-Q for the period ended June 30, 2017, and KemPharm&rsquo;s other Periodic and Current Reports filed with the Securities and Exchange Commission.&nbsp;KemPharm is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman; font-size: 10pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">###</font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL54" style="width: 99.9%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0%;">

		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Investor Contacts:</b></p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Media Contact:</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Jason Rando / Joshua Drumm, Ph.D.</p>

			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><u>Tiberend Strategic Advisors, Inc.</u></p>

			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">212-375-2665 / 2664</p>

			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><u>jrando@tiberend.com</u></p>

			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><u>jdrumm@tiberend.com</u></p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Daniel L. Cohen</p>

			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Executive VP, Government and Public Relations</p>

			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">KemPharm, Inc.</p>

			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">202-329-1825</p>

			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><u>dcohen@kempharm.com</u></p>
			</td>
		</tr>

</table>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1img002.jpg
<TEXT>
begin 644 ex99-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  G ,@# 2(  A$! Q$!_\0
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%T"UC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1img001.jpg
<TEXT>
begin 644 ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  U $T# 2(  A$! Q$!_\0
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MK%;V]TKNY R< '/0$UTLU]9V]Q%;W%W##-+GRT=PK/CT!ZU\^? ;X86GPO\
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=5E6JO5A11174<P4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
